Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema

• ClinicalTrials.gov Identifier: NCT04898309
• Recruitment Status: Withdrawn
• First Posted: May 24, 2021
• Last Update Posted: February 4, 2022
• Sponsor: AO GENERIUM
• Information provided by (Responsible Party): AO GENERIUM

Study Description

Brief Summary:

It is a placebo-controlled randomized trial to evaluate the efficacy and safety of GNR-038 in comparison with Berinert® in patients with hereditary angioedema

Condition or disease	Intervention/treatment	Phase
Hereditary Angioedema	Drug: GNR-038, 50 МЕ/ kg; Drug: GNR-038, 100 МЕ/ kg; Drug: Berinert®, 20 МЕ/ kg; Drug: Placebo; Drug: GNR-038. The dose will be selected according to results of stage 1 clinical trial.	Phase 2; Phase 3

Detailed Description:

Hereditary angioedema is a rare, potentially life-threatening genetically determined disease associated with a deficiency or impairment of the functional activity of the C1-esterase inhibitor (C1-inhibitor). The main clinical manifestation of hereditary angioedema is recurrent subcutaneous or submucosal swelling of various localization. Most often, the development of the disease is based on a mutation in the SERPING1 gene. The prevalence of the disease in the world ranges from 1:10 000 to 1:150 000. GNR-038 is a recombinant C1 inhibitor (rhC1INH), which is a complete structural and functional analog of the plasma C1 inhibitor. Phase I study results showed convincing safety and tolerability evidence of GNR-038.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 0 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: Two-stage study. In the first stage - 4 groups are presented. At the second stage - 2 study groups 200 HAE attacks to be randomized in 50 patients
• Masking: Double (Participant, Investigator)
• Masking Description: At the first stage - the study will be blinded, at the second stage - open-label
• Primary Purpose: Treatment
• Official Title: A Placebo-controlled Randomized Trial to Evaluate the Efficacy and Safety of GNR-038 in Comparison With Berinert® for Acute Attacks Relief in Patients With Hereditary Angioedema
• Estimated Study Start Date: December 1, 2021
• Estimated Primary Completion Date: May 31, 2023
• Estimated Study Completion Date: May 31, 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: Study stage 1: GNR-038, 50 МЕ/ kg; Recombinant C1 esterase inhibitor	Drug: GNR-038, 50 МЕ/ kg; A single intravenous infusion of GNR-038, 50 МЕ/ kg less than 5 hours after the onset of edema.; Other Name: Recombinant C1 esterase inhibitor, 50 МЕ/ kg
Experimental: Study stage 1: GNR-038, 100 МЕ/ kg; Recombinant C1 esterase inhibitor	Drug: GNR-038, 100 МЕ/ kg; A single intravenous infusion of GNR-038, 100 МЕ/ kg less than 5 hours after the onset of edema.; Other Name: Recombinant C1 esterase inhibitor, 100 МЕ/ kg
Experimental: Study stage 1: Berinert®, 20 МЕ/ kg; Human C1 esterase inhibitor	Drug: Berinert®, 20 МЕ/ kg; A single intravenous infusion of Berinert®, 20 МЕ/ kg less than 5 hours after the onset of edema.; Other Name: Human C1 esterase inhibitor
Experimental: Study stage 1: Placebo; Placebo	Drug: Placebo; A single intravenous infusion of Placebo less than 5 hours after the onset of edema.
Experimental: Study stage 2: GNR-038 in selected dose; Recombinant C1 esterase inhibitor	Drug: GNR-038. The dose will be selected according to results of stage 1 clinical trial.; A single intravenous infusion of GNR-038 less than 5 hours after the onset of edema.; Other Name: Recombinant C1 esterase inhibitor.
Experimental: Study stage 2: Berinert®, 20 МЕ/ kg; Human C1 esterase inhibitor	Drug: Berinert®, 20 МЕ/ kg; A single intravenous infusion of Berinert®, 20 МЕ/ kg less than 5 hours after the onset of edema.; Other Name: Human C1 esterase inhibitor

Outcome Measures

Primary Outcome Measures :

1. Time to symptoms relief onset of acute HAE attack within 24 hours after the end of the drug administration. [ Time Frame: 24 hours ]
   A persistent decrease in the intensity of symptoms by 20 mm from the initial level on the visual analogue scale (VAS) will be regarded as a relief of symptoms of HAE. 0 mm is the absence of symptoms, 100 mm is the maximum possible intensity of symptoms

Secondary Outcome Measures :

1. Time to complete resolution of the symptoms of an acute HAE attack within 24 hours after the end of the study drug administration. [ Time Frame: 24 hours ]
   Persistent absence of symptoms - 0 (zero) mm on the visual analogue scale (VAS). 0 mm is the absence of symptoms, 100 mm is the maximum possible intensity of symptoms
2. Time to minimum manifestation onset of acute HAE attack symptoms after the completion of study drug administration. [ Time Frame: 24 hours ]
   Persistent reduction in the intensity of symptoms below 20 (twenty) mm on the visual analogue scale(VAS). 0 mm is the absence of symptoms, 100 mm is the maximum possible intensity of symptoms
3. The proportion of HAE exacerbation episodes that achieved symptom relief after 1 hour and 4 (four) hours after the end of study drug administration. [ Time Frame: 1 hour; 4 hours. ]
4. The rate of attacks with HAE current localization relapse or with the occurrence of a new acute attack of a different localization within 24 (twenty-four) hours after the study drug administration. [ Time Frame: 24 hours ]
5. The rate of attacks that required additional administration of emergency drugs (human C1-esterase inhibitor or icatibant). [ Time Frame: 24 hours ]
6. The rate of attacks that did not respond therapeutically to the study drug administration [ Time Frame: 4 hours; 24 hours ]
   the lack of relief of HAE symptoms within 4 (four) hours after administration of the drug, the occurrence of a relapse of HAE of the current localization or the occurrence of a new acute attack of another localization within 24 (twenty-four) hours after drug administration, the need to use drugs that can weaken the symptoms of HAE (see drugs that are not recommended to treatment), within 24 (twenty-four) hours after drug administration.
7. The intensity of acute HAE attack symptoms within 24 (twenty-four) hours after study drug administration. [ Time Frame: 24 hours ]
   HAE intensity wiil be measured by visual analogue scale (VAS). 0 mm is the absence of symptoms, 100 mm is the maximum possible intensity of symptoms
8. Frequency of adverse events. [ Time Frame: 14 days ]
9. Frequency of anti-drug antibody formation. [ Time Frame: 7 and 14 days ]
10. The level of anti-drug antibodies neutralizing activity. [ Time Frame: 7 and 14 days ]
    Laboratory measurement of antidrug antibody with neutralixing activity.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria

1. Men and women 18 years and older at the time of signing the Informed Consent Form.
2. Availability of written informed consent signed by the patient prior to the start of any procedures related to the study.

3. Confirmed diagnosis of HAE:

   • C4 level <50% of the lower limit of the range of normal laboratory values and one of the points below:
   • the C1INH level <50% of the lower limit of the range of normal laboratory values, OR
   • the level of C1INH within normal values, while the level of functional activity of C1INH is below 50% of the lower limit of the range of normal values.
4. Localization of the edema in the abdominal cavity, in the face area (lips, eyelids, subcutaneous tissue), limbs, trunk or in the area of the external genitals in the anamnesis.
5. ≥4 HAE attacks requiring treatment or causing significant functional impairment for 2 consecutive months in the 3-month period prior to Screening, properly documented in the medical records.
6. Patient's consent to adhere to reliable methods of contraception.

Exclusion Criteria

1. Deviation of the C1q level below the normal limit.
2. B-cell lymphoproliferative diseases in the anamnesis or at the time of inclusion in clinical trial.
3. The presence of anti-C1INH autoantibodies.
4. Allergic reactions to the components of C1INH drugs or other blood components.
5. Glomerular filtration rate ≤59 ml/min/1.73 m2, calculated by the formula CKD-EPI Creatinine Equation (2009) (see Appendix).
6. The concentration of peripheral blood leukocytes >20*109/L.
7. Drug addiction, solvent abuse, alcoholism in the anamnesis or at the time of inclusion.
8. Participation in clinical trials of C1-esterase inhibitor drugs, blood transfusion and its components during the last 90 days prior to screening.
9. Participation in clinical trials of any other investigational drugs within the last 30 (thirty) days prior to screening.
10. Positive laboratory results for HIV and hepatitis B and C.
11. Pregnancy and lactation.
12. Diseases and conditions associated with thrombosis (myocardial infarction, transient ischemic attacks, deep and superficial vein thrombosis, and pulmonary embolism) less than 6 months before the start of the screening period, as well as an increased risk of arterial or venous thrombosis according to the study doctor's opinion.

13. Concomitant diseases and conditions that according to the study doctor's opinion put the patient's safety at risk when participating in the study, or that will affect the analysis of safety data if this disease/condition worsens during the study, including:

    • Mental illness;
    • Diseases of the immune and endocrine system that are not controlled by drug therapy (including decompensated diabetes mellitus and thyroid diseases);
    • Hematological diseases requiring chemotherapy;
    • Cancer or cancer in the past medical history, with the exception of cured basal cell carcinoma;
    • Decompensated liver diseases.

Contacts and Locations

Locations

Russian Federation

National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia

Moscow, Russian Federation, 115522

Moscow City Clinical Hospital 52

Moscow, Russian Federation, 123182

Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology

Moscow, Russian Federation, 630099

Rostov State Medical University

Rostov-on-Don, Russian Federation, 344022

LLC "Scientific Medical Center of General Therapy and Pharmacology"

Stavropol', Russian Federation, 355000

Sponsors and Collaborators

AO GENERIUM

Investigators

• Study Chair: Oksana A. Markova, MD; AO GENERIUM

More Information

Additional Information:

Clinical trial registry, Ministry of Health of Russian Federation 

Clinical trial registry 

• Responsible Party: AO GENERIUM
• ClinicalTrials.gov Identifier: NCT04898309
• Other Study ID Numbers: CIR-HAE-II-III; #210, April 16, 2 ( Other Identifier: Ministry of Health of Russian Federation )
• First Posted: May 24, 2021
• Last Update Posted: February 4, 2022
• Last Verified: January 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by AO GENERIUM:

Complement C1 Inhibitor Protein; Hereditary angioedema; Swelling; GNR-038; C1-inhibitor; Mutation; SERPING1 gene; HAE; Genetic disease; C1-INH deficiency; Hypersensitivity; Immune System Diseases; Genetic Diseases, Inborn; Immunologic Factors; Physiological Effects of Drugs; Complement Inactivating Agents; Immunosuppressive Agents; Angioedema; Angioedemas, Hereditary; Complement C1 Inactivator Proteins

Additional relevant MeSH terms:

Complement C1 Inhibitor Protein; Angioedema; Angioedemas, Hereditary; Vascular Diseases; Cardiovascular Diseases; Urticaria; Skin Diseases, Vascular; Skin Diseases; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases; Hereditary Complement Deficiency Diseases; Primary Immunodeficiency Diseases; Genetic Diseases, Inborn; Immunologic Deficiency Syndromes; Complement C1s; Complement C1 Inactivator Proteins; Immunologic Factors; Physiological Effects of Drugs; Complement Inactivating Agents; Immunosuppressive Agents